Aurobindo Pharma Ltd.

View in App
868.00 -8.05 ▼-0.9%

22 September 2023, 04:01:00 PM
Volume: 35,708

Company Profile

View details >>
Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.aurobindo.com
Market Cap 50,748.14 Cr.
Enterprise Value(EV) 49,525.46 Cr. 2023-03
Financial Indicators
Earnings per share (EPS) 33.75 Trailing Twelve Months Ending 2023-06
Price-Earning Ratio (PE) 25.72 Trailing Twelve Months Ending 2023-06
Industry PE 37.50 Trailing Twelve Months Ending 2023-06
Book Value / Share 467.84 Trailing Twelve Months Ending 2023-06
Price to Book Value 1.86 Calculated using Price: 868.00
Dividend Yield 0.35 Period Ending 2023-03
No. of Shares Subscribed 58.59 Cr. 585,938,609 Shares
FaceValue 1
About Aurobindo Pharma Ltd.
Aurobindo Pharma continues to be one of the world's fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. Also, it is building a diversified pipeline in high-margin specialty generic formulations segment.

Aurobindo Pharma Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Aurobindo Pharma Ltd. Performance

View details >>
1 Day
-0.92%
1 Week
-3.42%
1 Month
+3.07%
3 Month
+29.32%
6 Month
+81.17%
1 Year
+66.76%
2 Year
+18.70%
5 Year
+13.96%
10 Year
+819.69%

Aurobindo Pharma Ltd. Fundamental Ratios

View details >>
9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 35.29 32.53 27.63 23.02 18.47 18.52 27.53 11.38 7.50
Return on Capital Employed (%) 27.18 27.36 24.96 22.74 17.97 18.72 30.10 12.71 9.39
Return on Assets (%) 14.03 14.14 14.47 13.09 10.00 10.33 17.16 7.90 5.29

Aurobindo Pharma Ltd. Balance Sheet

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Shh. Funds 3,750 5,156 7,287 9,372 11,680 13,891 16,825 21,930 24,576 26,840
Non Curr. Liab. 1,494 1,592 584 102 594 358 555 807 903 867
Curr. Liab. 4,220 6,136 7,840 6,606 8,666 12,021 11,385 10,665 8,156 11,494
Minority Int. 26 26 3 2 2 2 0 -1 -2 12
Equity & Liab. 9,490 12,910 15,714 16,082 20,942 26,271 28,765 33,401 33,633 39,213
Non Curr. Assets 3,859 4,611 5,420 6,875 8,764 10,939 12,352 13,578 15,510 17,667
Curr. Assets 5,631 8,299 10,294 9,206 12,178 15,332 16,413 19,740 18,044 21,460
Misc. Exp. not W/O
Total Assets 9,490 12,910 15,714 16,082 20,942 26,271 28,765 33,401 33,633 39,213

Aurobindo Pharma Ltd. Profit and Loss

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-06 Rs. Cr. TTM
Net Sales 12,121 13,795 14,910 16,463 19,564 23,099 24,775 23,455 24,855 25,470
Other Income 97 204 116 102 155 192 381 323 291 401
Total Income 12,217 13,998 15,025 16,565 19,719 23,290 25,155 23,778 25,146 25,871
Total Expenditure -9,557 -10,607 -11,475 -12,691 -15,612 -18,234 -19,441 -19,071 -21,137 -21,571
PBIDT 2,660 3,392 3,550 3,874 4,107 5,056 5,714 4,707 4,009 4,300
Interest -160 -257 -67 -78 -263 -305 -74 -49 -140 -182
Depreciation -333 -392 -428 -558 -668 -967 -1,055 -1,127 -1,245 -1,292
Taxation -597 -721 -760 -818 -727 -899 -2,010 -726 -685 -769
Exceptional Items -88 -26 2,815 -128 -70
PAT 1,571 2,024 2,301 2,423 2,362 2,844 5,334 2,647 1,928 1,987
Minority Interest 5 2 0 0 0 1 1 1 0 1
Share Associate 3 -10
Other Related Items
Consolidated Net Profit 1,576 2,025 2,302 2,423 2,365 2,845 5,335 2,648 1,928 1,978
Adjusted EPS 27 35 39 41 40 49 91 45 33 34

Aurobindo Pharma Ltd. Cash Flow

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 646 1,237 1,420 3,279 1,955 1,651 4,381 3,329 5,016 2,387
Cash Fr. Inv. -819 -1,398 -1,445 -1,787 -1,927 -2,903 -1,568 599 -3,212 -3,978
Cash Fr. Finan. 118 93 365 -1,915 864 1,919 -1,947 -1,365 -2,969 1,814
Net Change -55 -68 340 -424 892 667 866 2,563 -1,164 223
Cash & Cash Eqvt 148 461 744 320 1,210 1,876 2,747 5,330 4,163 4,392

Aurobindo Pharma Ltd. Shareholding Pattern

View details >>
9 Qtrs 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%)
Promoter 51.83 51.83 51.83 51.83 51.83 51.83 51.83 51.83 51.83
Public 48.17 48.17 48.17 48.17 48.17 48.17 48.17 48.17 48.17
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 20.66 22.98 22.97 14.05 14.97 14.92 16.15 17.90 19.16

Aurobindo Pharma Ltd. Announcements

View details >>
Thu, 21 Sep 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform that the officials of the Company will be participating in the f investor / analyst meeting on September 26 2023.
Wed, 20 Sep 2023
Completion Of US FDA Inspection At Unit IV Of APL Healthcare Ltd
The USFDA inspected Unit IV a formulation manufacturing facility of APL Healthcare Limited a wholly owned subsidiary of the Company from September 13 to September 19 2023. At the end of the inspection a Form 483 was issued with one observation which is procedural in nature.
Mon, 18 Sep 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of Notice published in news papers informing shareholders about transfer of shares to IEPF.

Aurobindo Pharma Ltd. Technical Scans

View details >>
Fri, 22 Sep 2023
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week High Zone Close Within 52 Week High Zone
Closing Below Previous Low for 2 Days Closing Below Previous Low for 2 Days
Making Lower Lows for 2 Days Making Lower Lows for 2 Days
High Increase in 3 Months High Increase in 3 Months

Aurobindo Pharma Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 271,508.75 1,131.60 -1.3%
Divi's Laboratories Ltd. 98,393.27 3,708.40 -1.0%
Cipla Ltd. 95,796.29 1,184.35 -1.9%
Dr. Reddy's Laboratories Ltd. 92,004.31 5,516.35 -2.7%
Apollo Hospitals Enterprise Ltd. 71,703.97 5,003.05 -0.3%
Mankind Pharma Ltd. 70,167.07 1,751.60 +0.7%
Torrent Pharmaceuticals Ltd. 62,653.02 1,853.55 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-06 32.19 1,131.60 -1.3%
Divi's Laboratories Ltd. Consolidated 2023-06 66.64 3,708.40 -1.0%
Cipla Ltd. Consolidated 2023-06 30.73 1,184.35 -1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-06 19.48 5,516.35 -2.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-06 107.60 5,003.05 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 54.74 1,751.60 +0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-06 49.79 1,853.55 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-06 4.68 1,131.60 -1.3%
Divi's Laboratories Ltd. Consolidated 2023-06 7.50 3,708.40 -1.0%
Cipla Ltd. Consolidated 2023-06 3.93 1,184.35 -1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-06 3.75 5,516.35 -2.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-06 11.47 5,003.05 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 5.73 1,751.60 +0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-06 9.54 1,853.55 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,131.60 -1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,708.40 -1.0%
Cipla Ltd. Consolidated 2023-03 0.02 1,184.35 -1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 5,516.35 -2.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 5,003.05 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 1,751.60 +0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 1,853.55 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,131.60 -1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,708.40 -1.0%
Cipla Ltd. Consolidated 2023-03 12.85 1,184.35 -1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,516.35 -2.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,003.05 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,751.60 +0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 1,853.55 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,131.60 -1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,708.40 -1.0%
Cipla Ltd. Consolidated 2023-03 12.85 1,184.35 -1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,516.35 -2.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,003.05 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,751.60 +0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 1,853.55 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,131.60 -1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,708.40 -1.0%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,184.35 -1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 5,516.35 -2.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 5,003.05 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 1,751.60 +0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 1,853.55 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,131.60 -1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,708.40 -1.0%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,184.35 -1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 5,516.35 -2.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 5,003.05 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 1,751.60 +0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 1,853.55 -1.1%

Aurobindo Pharma Ltd. FAQ's

What is Aurobindo Pharma share price?
Can I buy Aurobindo Pharma shares now?
What is the Dividend Yield of Aurobindo Pharma?
What is the Market Cap of Aurobindo Pharma?
What are the key metrics to analyse Aurobindo Pharma?
What is the 52 Week High and Low of Aurobindo Pharma?
What is the trend of Aurobindo Pharma share price?